ORIC Pharmaceuticals Leadership

Pratik is Chief Medical Officer of ORIC Pharmaceuticals, which is discovering and developing therapies to overcome resistance in cancer. Prior to joining ORIC in September 2018, Pratik was Chief Medical Officer at Ignyta until its acquisition by Roche in February 2018. While at Ignyta, he led clinical and nonclinical development, as well as regulatory strategy for Ignyta’s portfolio of precision medicines in oncology, including entrectinib, a novel CNS-penetrant TRK and ROS1 inhibitor. Pratik’s background encompasses broad scientific and management experience in clinical development with a deep understanding of oncology. He served as Chief Medical Officer at Fate Therapeutics, where he led the clinical development of novel stem cell therapies for the treatment of hematologic malignancies and other rare diseases, and was involved in leadership positions for the development of multiple innovative marketed cancer therapies, including Treanda (bendamustine), Zevalin (ibritumomab tiuxtetan), and Rituxan (rituximab). Prior to joining industry, Pratik held academic and clinical positions at Harvard Medical School and Massachusetts General Hospital, where he was a member of the bone marrow transplant unit. He completed an internship and residency training in internal medicine at Massachusetts General Hospital and his oncology fellowship at the Dana Farber-Partners combined program. Pratik holds a B.S. from Yale University, an M.D. from Harvard Medical School, and an M.S. in Epidemiology from the Harvard School of Public Health.

Mr. Piscitelli brings to ORIC 20 years of industry experience, including debt and equity financings, in-licensing transactions, acquisitions, marketing partnerships and commercial product launches (XTANDI® and Tarceva®). Prior to joining ORIC, Mr. Piscitelli was CFO of AnaptysBio, a NASDAQ-listed biotechnology company, where he helped raise over $500 million in an IPO and follow-on financings. Prior to AnaptysBio, Mr. Piscitelli was Vice President of Finance, Strategy and Investor Relations at Medivation and played a key role in its acquisition by Pfizer. Previously, he served as Senior Director of Collaborations and Operations Finance at Astellas Pharma. Prior to that, Mr. Piscitelli served in various roles of increasing responsibility culminating as the Vice President, Treasury & Management Finance at OSI Pharmaceuticals, and played a significant role in their acquisition by Astellas. Mr. Piscitelli began his career with KPMG and is a certified public accountant. He earned a bachelor’s degree in accounting and an MBA from Hofstra University.

Dr. Friedman brings to ORIC over 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics, drug discovery, pharmacology and biomarkers. During her 15-year career at Genentech, she held roles of increasing responsibility and was most recently head of translational oncology for Genentech Research and Early Development (gRED), where her team advanced more than 20 programs into clinical development. Dr. Friedman also sat on multiple cross-functional leadership teams tasked with strategic and technical review of Genentech’s oncology research pipeline projects. Prior to Genentech, Dr. Friedman held various scientific leadership roles at Exelixis. She is an inventor on 24 issued patents and author on 90 peer-reviewed publications. She completed post-doctoral work at the University of Washington and at Cambridge University and earned a PhD in molecular and cell biology from UC Berkeley. She currently serves on the board of directors of Project Scientist, a non-profit organization serving girls in STEM.

Dr. Friedman brings to ORIC over 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics, drug discovery, pharmacology and biomarkers. During her 15-year career at Genentech, she held roles of increasing responsibility and was most recently head of translational oncology for Genentech Research and Early Development (gRED), where her team advanced more than 20 programs into clinical development. Dr. Friedman also sat on multiple cross-functional leadership teams tasked with strategic and technical review of Genentech’s oncology research pipeline projects. Prior to Genentech, Dr. Friedman held various scientific leadership roles at Exelixis. She is an inventor on 24 issued patents and author on 90 peer-reviewed publications. She completed post-doctoral work at the University of Washington and at Cambridge University and earned a PhD in molecular and cell biology from UC Berkeley. She currently serves on the board of directors of Project Scientist, a non-profit organization serving girls in STEM.